Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

ClinicalTrials.gov ID: NCT00642278

Public ClinicalTrials.gov record NCT00642278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm

Study identification

NCT ID
NCT00642278
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Enrollment
451 participants

Conditions and interventions

Interventions

  • Canagliflozin (JNJ-28431754) Drug
  • Placebo Drug
  • Sitagliptin Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2008
Primary completion
Dec 31, 2008
Completion
Dec 31, 2008
Last update posted
Jul 18, 2013

2008 – 2009

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
30
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Mesa Arizona
Not listed Tucson Arizona
Not listed Encinitas California
Not listed Lincoln California
Not listed Los Angeles California
Not listed Merced California
Not listed Roseville California
Not listed Denver Colorado
Not listed Golden Colorado
Not listed Hollywood Florida
Not listed Jacksonville Florida
Not listed Boise Idaho
Not listed Nampa Idaho
Not listed Topeka Kansas
Not listed Haverhill Massachusetts
Not listed Cherry Hill New Jersey
Not listed Albuquerque New Mexico
Not listed New Hyde Park New York
Not listed Salisbury North Carolina
Not listed Oklahoma City Oklahoma
Not listed Tulsa Oklahoma
Not listed Portland Oregon
Not listed Greer South Carolina
Not listed Dallas Texas
Not listed Houston Texas
Not listed New Braunfels Texas
Not listed Odessa Texas
Not listed San Antonio Texas
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00642278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2013 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00642278 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →